

## Public web site

---


**08/03/2019**

This is the document associated to the deliverable D6.2 “Web site” that is available at the following URL: <https://www.strituvad.eu/>

Author: Marco Viceconti	replaces version	C	from	n.a.	Page
	valid from date (dd/mm/yyyy)		08/03/2019		1 / 7
	Recipient		Public		

## Domain name

The domain strituvad.eu has been registered in name of Etna Biotech SRL:



**.eu**  
Go to eurid.eu

strituvad.eu Search English (en) ▼

**WHOIS DATA**  
Not available for registration

Domain name	strituvad.eu
Status	In Use ?
Registered	10 Dec 2018
Registrar	Register.it S.p.A.

**NAME SERVERS**

**REGISTRANT AND CONTACTS**  
Etna Biotech SRL ▼


Contact type	Registrant
Organisation	Etna Biotech SRL
Language	Italian
Address	Catania CT IT
Email	info@etnabiotech.it

**Figure 1.** Left: output of a WHOIS request, showing the registration data of the Strituvad.eu domain. Right: temporary home page of the web site.

The domain name originally suggested in the proposal, “strituvad-isct.eu” was discarded because no other project in the field is using the convention to append ISCT to the domain name; also the community is steering away from the acronym originally proposed in the Avicenna Roadmap (In Silico Clinical Trials, ISCT) in favour of a more generic In Silico Trials, which includes both pre-clinical and clinical testing.

## Logo

The project logo that was used for the proposal was found not ideal for our communication strategy. Thus, a restyling was conducted, and the final result is reproduced in figure 2. From now on this will be the official logo of the project; this and other digital materials are shared with all members of the consortium, in a “Visual Identity” folder in the private space of the web site. For consistency, the new logo will also appear in all new deliverables, starting from this one.



**Figure 2.** Restyled logo of the STriTuVaD project.

## Structure

The web site <https://www.strituvad.eu/> was organised around a template style called “parallax scrolling”, where the background images scrolls more slowly than the foreground, producing a 3D effect. This is one of the most popular styles nowadays, and users are familiar with it.

The web site is organised around the stakeholders: Patients & Public, Clinicians, Industry, Researchers, Project, News & Events. For each we provide contents that are specifically tailored for that stakeholder group, both in term of content and in term of language. The section project contains all information on the project: The public ones are under the “About the Project” submenu; the private ones are accessible in a shared files repository that is password-protected.

Author	Marco Viceconti	Valid from (dd/mm/yyyy)	Pag.
		08/03/2019	3 / 7



**Figure 3.** Snapshot of the top of the home page (as per 4-3-2019).

The detailed hierarchy of the website (as per 4-3-2019) is:

1. Home (scrolling page)
  - 1.1. summary
  - 1.2. Latest News
  - 1.3. Slideshow Gallery
  - 1.4. Six targeted summaries linked to sections
  - 1.5. Newsletter & Social subscriptions
  - 1.6. Partners logos
  - 1.7. Contact form
2. Patients & Public (scrolling page with anchors)
  - 2.1. A summary for patients and public
  - 2.2. What is tuberculosis
  - 2.3. Why do we need better therapies?
  - 2.4. Why do we need better ways to test new therapies?
  - 2.5. In silico Trials, a layperson description
3. Clinicians (scrolling page with anchors)
  - 3.1. A summary for Clinicians

Author	Marco Viceconti	Valid from (dd/mm/yyyy)	Pag.
		08/03/2019	4 / 7

- 3.2. Adjuvant therapies for TB treatment
- 3.3. A project clinical description
4. Industry (scrolling page with anchors)
  - 4.1. A summary for Industries
  - 4.2. The opportunity of in silico for the pharma industry
  - 4.3. Industrial partners
5. Researchers
  - 5.1. Intro page with links to subpages
  - 5.2. Link to Project page
  - 5.3. Link to Consortium page
  - 5.4. In Silico World
  - 5.5. Objectives
  - 5.6. Technical Deliverables
  - 5.7. Papers & Publications
6. Project (scrolling page)
  - 6.1. Project scope
  - 6.2. About us
  - 6.3. Project details
  - 6.4. Public Deliverables and Reports
  - 6.5. MEMBER AREA (protected with password, only for partners use)
7. News & Events (blogging page with articles)
8. About us
  - 8.1. Consortium (list of all partners with descriptions and contacts)
  - 8.2. Contacts (link to contact form in Home Page)



## CLINICIANS

- Top
- Adjuvant therapies
- Clinical description

The goal of the STRITUVAD project is to test the reliability of performing at least part of clinical trials of new combinatory therapies for tuberculosis *in silico*, i.e. through computer modelling and simulation, which would dramatically reduce the costs involved, and ultimately provide more affordable therapies. A full-scale clinical trial will be conducted to test two new therapeutic vaccines to be used as adjuvant of standard chemotherapy, to reduce the duration of the therapy and to decrease the chances of relapses. For each of the patients enrolled, a full-scale computer simulation of the disease progression and of the effect of these therapies on it will be realized, in order to predict the duration of the therapy and the incidence of relapses. The model predictions will then be compared blindly to the clinical results, in order to quantify the predictive accuracy of this new technology. If such accuracy is found to be sufficiently high, we will explore various future scenarios where the computer model could replace at least part of the animal and clinical testing required to evaluate the efficacy of a new therapy for tuberculosis. We hope this will reduce the cost of such new therapies, making them more affordable for patients living in lower-income countries.



## PATIENTS & PUBLIC

- Top
- Tuberculosis
- Therapies
- Testing
- In Silico trials

**Tuberculosis** is an infectious disease that spreads through the air. When one is infected, the disease can remain dormant for long time, with no or little symptoms, but when the infection becomes active, it is severely debilitating and - if not properly cured - it is lethal.

Tuberculosis affects millions of people worldwide, more frequently in lower-middle income countries like India, but it also represents a potential public health threat for developed countries, due to the increased mobility and the more frequent appearance of mutations of the disease, that are resistant to all standard therapies. For these and other reasons, we desperately **need better therapies**.

The cost of developing new drugs grew exponentially in the last 30 years, for a number of reasons: one study suggests that it may take today as much as 2.9 billion dollars to develop, test for safety and efficacy, and commercialise a new drug. If we want to develop better therapies that can be sold at prices that also lower income countries can afford, we need to find **better ways to test new therapies**.

The goal of the STRITUVAD project is to develop new technologies that makes possible to test the efficacy



Author	Marco Viceconti	Valid from (dd/mm/yyyy)	Pag.
		08/03/2019	5 / 7



Figure 4. a sample of some web pages (as per 4-3-2019).

## Content Management System

The StriTuVad.eu web site is being developed using a web development platform called WIX, which allows rapid development of HTML5 web sites without any programming, simply using drag and drop tools. This will make possible, where necessary, also for other partners of the consortium to curate some of the contents they are expert of without the need for a dedicated web master.

Author	Marco Viceconti	Valid from (dd/mm/yyyy)	Pag.
		08/03/2019	6 / 7

## Web site updating

Initially all new contents will be prepared by the Communication Officer at partner UNIBO (possibly from material provided by other partners in the consortium), revised by an editorial board composed by the communication officer, the WP6 lead (Prof Viceconti, UNIBO), the coordinator representative (Dr Fichera) and the scientific coordinator (Prof Pappalardo), and then finally approved by the Coordinator on behalf of the consortium, before publication.

The news section will be linked to the social network channels we manage as StriTuVaD dissemination team, in order to have consistent news updates across all platforms. We will also post there all events information, all press releases, and all the other in-depth articles we will write for the periodic newsletter. When the periodic newsletter is launched, also the past issues will be stored permanently under this section. Moreover, regular updates of the image gallery in the home page with fresh material will be carried on.

For the more static contents, we will update them every time we receive any feedback or new information that recommends a revision. In addition, every six months the communication officer will review the metrics that we use to monitor the communication and compare them with our communication strategy (detailed in deliverable D6.1). As part of this periodic review, we will also review the whole web site contents, aligning the content to the needs of our evolving communication strategy.

Author	Marco Viceconti	Valid from (dd/mm/yyyy)	Pag.
		08/03/2019	7 / 7